Wound_care.png

Tissue regeneration and wound care in Leeds City Region

Develop and commercialise new tissue regeneration and wound care technologies and access a rapidly developing market within the health and medical technology sector.

Leeds City Region is a perfect opportunity to test and translate your tissue regeneration and wound care technologies, products and devices into use in the NHS (National Health Service) and private healthcare sector.

It is an ideal location for your medtech business with:

  • access to all the skills you need

  • a strong entrepreneurial community

  • a world-leading cluster of specialist research and clinical organisations

Access all this to support you through the lifecycle of your investment, from R&D to commercialisation of your technologies.

wound_care_2.png

Location:

Leeds City Region (West Yorkshire)

Investment type:

Foreign direct investment

Sector:

MedTech, Healthcare and life sciences

Take advantage of this opportunity to expand your business in the UK

Find out how

Sector and market opportunity

There is a growing need for new products and technologies that can accelerate repair and regeneration of human tissue. The annual cost to the NHS of managing wounds and associated comorbidities is £5.3 billion. Leeds City Region offers expertise in regenerative and personalised medicine, wound care, orthopaedics and dentistry, tissue scaffolds and technology convergence. The region is primed to support investing companies from concept to commercialisation, including fundamental research, feasibility studies, clinical trials and manufacturing.

Growth prospects

Regenerative medicine has enormous potential. The global wound care market is projected to reach £20.2 billion by 2026 from £14 billion in 2021, at a compound annual growth rate of 7.6% during the forecast period.

The UK cell and gene therapy market is predicted to increase from £300 million to about £10 billion by 2035.

The UK is the third largest medical device market in Europe, and the sixth biggest globally. From an estimated value of £7 billion in 2015, it now exceeds £12 billion.

Location

Located in the centre of the UK, Leeds City Region offers easy access to a cluster of international firms and to over 650 health and life sciences companies, including 250 medtech and 65 digital health companies. The cluster features a broad range of capabilities such as artificial intelligence, medical devices, digital health, regenerative medicine, biomaterials, tissue scaffolds, bioengineering, and cell culture. The Leeds City Region is also home to five NHS headquarters including NHS England, NHSX and NHS Digital.

Connectivity

Fly to major cities within the UK, Europe and worldwide via Leeds-Bradford Airport.

Connect by road to the Midlands in 2 hours and London in under 4 hours, via the M1.

Travel to London in just over 2 hours via fast and frequent rail links.

A business can reach 76% of the UK population by HGV in 4.5 hours.

Local talent and skills

Leeds City Region has the largest workforce in medtech-related industries outside of the South East of England with 7,000 people employed.

Five higher education institutes in the region offer courses linked to the tissue regeneration and wound care sector.

About 21,000 graduates per year are ready to join the workforce, with degrees in related subjects such as medicine and dentistry and biological sciences.

Research and expertise

From fundamental research to commercialisation, Leeds City Region has everything to take technologies from concept to market. Major innovation centres offer expertise in the tissue repair and regeneration field and capabilities to help your company.

They include:

  • Centre for Skin Sciences at the University of Bradford
  • Centre for Biomedical Science Research at Leeds Beckett University
  • Institute of Medical and Biological Engineering at the University of Leeds
  • Grow Medtech at the University of Leeds
  • Institute of Skin Integrity and Infection Prevention at the University of Huddersfield

The nationally-funded EPSRC Centre for Doctoral Training in Tissue Engineering and Regenerative Medicine is based at the University of Leeds. It develops regenerative therapies and devices as well as providing training for the medical and biological engineers of the future.

Region Spotlight
North of England

North-of-England.jpg

The North of England is recognised as a global centre for creativity and design and attracts thriving international investment. This heritage of expertise and manufacturing know-how is well established on the world stage, and historically gave birth to the Industrial Revolution.

View all investment opportunities in North of England

Local and national government support

The UK government’s Life Sciences Vision aims to tackle future disease challenges including cancer, obesity, dementia and ageing; secure jobs and investment; and transform the UK into the leading global hub for life sciences. It will target areas where the UK has, or could develop, a competitive advantage, such as cell and gene therapies, oligonucleotides, viral vectors, advanced diagnostics, and wound care. Local support is available through the Leeds City Region Enterprise Partnership.

Success stories

DePuy Synthes (part of Johnson & Johnson)

DePuy Synthes is one of the largest orthopaedics companies in the world. It has a long-standing research partnership with the world-leading Institute of Medical and Biological Engineering at the University of Leeds. This has led to improved understanding of joint replacements for millions of patients worldwide, new simulation test methods and equipment, and improved international ISO standards.

Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine and manufactures tissue repair and regeneration products for wound care and orthopaedics applications and other medical areas. Tissue Regenix was formed in 2006 as a spin-out from the University of Leeds. The company has a manufacturing centre based in Leeds and is now listed on the London Stock Exchange with revenue reaching £13 million in 2019.

Systagenix

Systagenix develops advanced wound care products for the management and healing of chronic and acute surgical wounds. The company offers a wide range of wound care products to meet the needs of health care professionals and patients. It supplies more than 20 million wound dressings a month in more than 100 countries.

Take advantage of this opportunity to expand your business in the UK

Find out how

Other opportunities